AKTX Stock Analysis: Buy, Sell, or Hold?
AKTX - Akari Therapeutics plc ADR (0.01 USD)
$13.40
-1.42 (-9.58%)
▼
5d:
-11.08%
30d:
+325.4%
90d:
+5746.42%
WAIT
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When AKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AKTX is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AKTX is down 11.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKTX is currently trading at $13.40, which is considered fair relative to its 30-day fair value range of $4.66 to $16.51.
Technical Outlook: Technically, AKTX is in a strong uptrend. The price is currently testing key support at $13.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.78 (+99.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKTX is in a strong uptrend. The price is currently testing key support at $13.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.78 (+99.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.66 -
$16.51
Company Quality Score
50/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BEARISH: Downward momentum (-9.6%)
- BULLISH: Trading 99.9% below Wall St target ($26.78)
- WARNING: Recommendation downgraded due to -11.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.66 -
$16.51
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$13.00
Resistance Level
$16.72
Current Trend
Strong Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.73
Wall Street Target
$26.78
(+99.9%)
Share & Embed Analysis
Last updated: June 13, 2026 12:55 PM ET
Data refreshes hourly during market hours. Next update: 1:55 PM
Data refreshes hourly during market hours. Next update: 1:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 48 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$295 | 52 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 62 BUY |
